Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyureaAbdulraheem Yacoub, Ronald Hoffman, John Mascarenhas et al.|Blood|2019Cited by 175
Impact of the rs1024611 Polymorphism of CCL2 on the Pathophysiology and Outcome of Primary MyelofibrosisElena Masselli, Marco Vitale, Giuliana Gobbi et al.|Cancers|2021Cited by 14
Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line SettingsAbdulraheem Yacoub, Robert S. Hoffman, John Mascarenhas et al.|Blood|2019Cited by 5